Aspira Women's Health Inc. (AWHL) stock
Close on Oct 19, 2026Market cap $9.91MP/E –Yield –
Aspira Women's Health Inc. reported revenue of $170.00K for the twelve months to Jun 30, 2026. Free cash flow was -$7.05M. At the latest close the market valued the company at $9.91M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.91M
- P/E ratio
- –
- Price to sales
- 58.31
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -71.08%
Fundamentals
- Revenue
- $170.00K
- Net income
- -$10.01M
- EPS, diluted
- -$0.31
- Free cash flow
- -$7.05M
- Book value per share
- -$0.16
- Diluted shares
- 44M
Trading
- Previous close
- $0.23
- Open
- $0.23
- Day's range
- $0.22 – $0.23
- Volume
- 2,102
- Average volume (20 days)
- 7,751
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | AWHL | S&P 500 | Difference | AWHL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.4% | +0.6% | −11.0 pts | ||
| 3 months | -41.2% | +3.4% | −44.6 pts | ||
| Year to date | -64.4% | +13.3% | −77.7 pts | ||
| 1 year | -56.1% | +16.6% | −72.7 pts | ||
| 3 years | -96.1% | +86.4% | −182.5 pts | -66.0% | +23.1% |
| 5 years | -99.5% | +81.9% | −181.4 pts | -65.8% | +12.7% |
| 10 years | -98.7% | +318.9% | −417.5 pts | -35.2% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aspira Women's Health filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- News
- Results
- News
- Results
About Aspira Women's Health
In Vitro & In Vivo Diagnostic Substances
Aspira Women’s Health Inc. develops and commercializes diagnostic tests focused on women's gynecologic health. The company specializes in the risk assessment and differential diagnosis of gynecologic diseases, primarily ovarian cancer and conditions such as endometriosis and pelvic masses. Its commercial offerings and pipeline include diagnostic solutions such as Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, and OVAinform, as well as the Aspira Synergy platform. The company provides laboratory-developed tests through its dedicated laboratory facility, Aspira Labs.
Company profile, executives and historyAspira Women's Health stock: common questions
What is Aspira Women's Health's stock price?
AWHL closed at $0.22 on Oct 19, 2026, down 2.61% on the day.
What is Aspira Women's Health's market cap?
Aspira Women's Health was worth $9.91M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is AWHL's P/E ratio?
Aspira Women's Health lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.31), so it has no meaningful P/E ratio.
How much revenue does Aspira Women's Health make?
Aspira Women's Health reported revenue of $170.00K for the twelve months to Jun 30, 2026.
Does Aspira Women's Health pay a dividend?
No. Aspira Women's Health has not paid a cash dividend over the last twelve months.
How has AWHL stock performed over the past year?
Including dividends, AWHL returned -56.1% over the past year, against +16.6% for the S&P 500.
Who are Aspira Women's Health's competitors?
Companies most similar to Aspira Women's Health by business, industry and size include IMDX, CLDX, CDIO, ONCO, ALLR.
See a number that looks wrong?